Articles by Nichole Tucker
Explore expert insights on bispecifics, CAR T-cell therapy, and emerging regimens for B-cell lymphomas.
Hematology/oncology fellow Joseph Van Galen, MD, is investigating the mechanisms behind immune-related adverse events.
Next-gen BCL-2 inhibitors show promise in RRMM as venetoclax struggles with OS in phase 3 BELLINI study.
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Ruxolitinib shows durable benefit and long-term safety in steroid-refractory chronic GVHD, REACH3 finds.
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
Bexmarilimab shows promising responses in high-risk MDS, with up to 85% ORR in the BEXMAB phase 2 study.
Luspatercept shows longer survival and transfusion independence in ESA-naïve lower-risk MDS, COMMANDS trial.
Vinayak (Vinay) Prasad, MD, MPH, has been appointed director of the FDA Center for Biologic Evaluation and Research.
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Cilta-cel improves PFS and OS in len-refractory MM across subgroups, including high-risk cytogenetics, per CARTITUDE-4.
IME shows strong efficacy in LR-MDS, offering transfusion independence in heavily pretreated, ESA-ineligible patients.
EPCOR shows durable remission and survival at 2 years in R/R LBCL, with promising safety from fixed-duration treatment.
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
CLL treatment is evolving. Dr. Ryan Jacobs shares why decisions now weigh indefinite therapy vs. time-defined options.
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.